

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

<b>1. Name and Address of Reporting Person*</b> <u>Kalb Michael Wayne</u> <hr/> (Last) (First) (Middle) <u>C/O AMARIN PHARMA, INC.</u> <u>1430 ROUTE 206</u> <hr/> (Street) <u>BEDMINSTER NJ 07921</u> <hr/> (City) (State) (Zip)	<b>2. Issuer Name and Ticker or Trading Symbol</b> <u>AMARIN CORP PLC/UK [ AMRN ]</u>	<b>5. Relationship of Reporting Person(s) to Issuer</b> (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>SVP and CFO</u>
	<b>3. Date of Earliest Transaction (Month/Day/Year)</b> <u>01/31/2019</u>	
<b>4. If Amendment, Date of Original Filed (Month/Day/Year)</b>		

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Ordinary Shares <sup>(1)(2)</sup>	01/31/2019		M		29,000 <sup>(3)</sup>	A	(4)	46,486	D <sup>(5)</sup>	
Ordinary Shares <sup>(1)(2)</sup>	01/31/2019		M		26,000 <sup>(6)</sup>	A	(4)	72,486	D <sup>(5)</sup>	
Ordinary Shares <sup>(1)(2)</sup>	01/31/2019		F <sup>(7)</sup>		26,935	D	\$16.94	45,551	D <sup>(5)</sup>	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Restricted Stock Units <sup>(8)</sup>	\$0.00	01/31/2019		M		29,000		(3)	(4)	Ordinary Shares <sup>(2)</sup>	29,000	\$0.00	29,000	D	
Restricted Stock Units <sup>(8)</sup>	\$0.00	01/31/2019		M		26,000		(6)	(4)	Ordinary Shares <sup>(2)</sup>	26,000	\$0.00	52,000	D	
Restricted Stock Units <sup>(8)</sup>	\$0.00	02/01/2019		A		38,200		(9)	(4)	Ordinary Shares <sup>(2)</sup>	38,200	\$0.00	38,200	D	
Stock Option (Right to Buy)	\$16.88	02/01/2019		A		53,500		(10)	02/01/2029	Ordinary Shares <sup>(2)</sup>	53,500	\$0.00	53,500	D	

**Explanation of Responses:**

- There are no market sales of securities reported on this Form 4.
- The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- On February 1, 2017, the Reporting Person was granted 87,000 restricted stock units (the "RSUs") under the Amarin Corporation plc 2011 Stock Incentive Plan (the "Plan"). These RSUs vest in three equal installments on each of January 31, 2018, January 31, 2019 and January 31, 2020. The second vesting event occurred on January 31, 2019.
- Not applicable.
- Please see the section titled "Remarks" below for additional information.
- On February 1, 2018, the Reporting Person was granted 78,000 RSUs under the Plan. These RSUs vest in three equal installments on each of January 31, 2019, January 31, 2020 and January 31, 2021. The first vesting event occurred on January 31, 2019.
- Represents withholding by the Issuer of shares in respect of tax liability incident to the vesting of a security issued in accordance with Rule 16b-3, and not a market sale of securities.
- Each RSU represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion.
- On February 1, 2019, the Reporting Person was granted 38,200 RSUs under the Plan. These RSUs vest in three equal installments on each of January 31, 2020, January 31, 2021 and January 31, 2022.
- On February 1, 2019, the Reporting Person was granted an option to purchase 53,500 Ordinary Shares under the Plan. The shares subject to this option shall vest and become exercisable in 16 equal quarterly installments starting on May 15, 2019.

**Remarks:**

In the case of a Change of Control (as defined in the Plan), the grants described in this Form 4 vest in full. As of the date of this Form 4, the Reporting Person owns or holds the right to acquire an aggregate of 1,013,251 Ordinary Shares of the Issuer in the form of Ordinary Shares, stock options and Restricted Stock Units granted under the Plan, including but not limited to, certain performance-based Restricted Stock Units that are earned only if product revenues reach pre-defined annual milestone levels ranging from \$300 million (as previously disclosed) to \$1.0 billion and, in certain cases, then vest only if the recipient remains with the company for an extended period of time.

/s/ Joseph Kennedy, by power 02/01/2019  
of attorney

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**